Added to YB: 2025-12-09
Pitch date: 2025-12-05
HROW [neutral]
Harrow, Inc.
+2.13%
current return
Author Info
MVC Investing is a long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Sign up for the newsletter.
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$46.08
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
growth
Harrow: Takeaways From This Week’s Investor Conference
HROW (update): MELT acquisition expands beyond ophthalmology into $100M+ procedural sedation market w/ FDA Special Protocol Agreement & 'ultra-low-risk' NDA path. VEVYE growth accelerating w/ 30M+ lives formulary access Jan 1, doubling salesforce. Biosimilars targeting 3-4% Lucentis/Eylea share = $240-320M revenue opportunity leveraging existing retina footprint.
Read full article (3 min)